Jessica Fye
Stock Analyst at JP Morgan
(3.71)
# 810
Out of 4,732 analysts
175
Total ratings
49.55%
Success rate
7.29%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Overweight | $28 → $24 | $21.93 | +9.44% | 5 | Jan 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $503 → $500 | $422.00 | +18.48% | 7 | Dec 23, 2024 | |
| MRNA Moderna | Maintains: Underweight | $59 → $45 | $34.06 | +32.12% | 11 | Nov 26, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $124 → $122 | $111.93 | +9.00% | 10 | Nov 26, 2024 | |
| INSM Insmed | Maintains: Overweight | $74 → $83 | $72.51 | +14.47% | 6 | Nov 22, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $81 → $89 | $126.20 | -29.48% | 7 | Nov 4, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $110 → $109 | $61.53 | +77.15% | 3 | Oct 30, 2024 | |
| INCY Incyte | Maintains: Neutral | $65 → $71 | $71.93 | -1.29% | 5 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Neutral | $32 → $26 | $29.47 | -11.77% | 6 | Oct 25, 2024 | |
| ASND Ascendis Pharma | Maintains: Overweight | $180 → $174 | $128.13 | +35.80% | 7 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.89 | +203.34% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $57 | $54.80 | +4.01% | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $55 | $31.43 | +74.99% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $248 → $280 | $246.27 | +13.70% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $202 | $121.18 | +66.69% | 3 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $66 | $29.02 | +127.43% | 4 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $37.35 | +44.58% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $46.95 | -16.93% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $300 | $358.93 | -16.42% | 14 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $9.36 | +38.89% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $26.17 | -35.04% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.89 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $9.88 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.21 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.56 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $10 | $7.45 | +34.23% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $32.66 | +132.70% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $204 → $240 | $4.65 | +5,061.29% | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.85 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $0.94 | +2,240.43% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.69 | +914.49% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $12.74 | +111.93% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.62 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.40 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.55 | - | 4 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.25 | - | 1 | Feb 8, 2018 |
Denali Therapeutics
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $21.93
Upside: +9.44%
Vertex Pharmaceuticals
Dec 23, 2024
Maintains: Overweight
Price Target: $503 → $500
Current: $422.00
Upside: +18.48%
Moderna
Nov 26, 2024
Maintains: Underweight
Price Target: $59 → $45
Current: $34.06
Upside: +32.12%
BioNTech SE
Nov 26, 2024
Maintains: Neutral
Price Target: $124 → $122
Current: $111.93
Upside: +9.00%
Insmed
Nov 22, 2024
Maintains: Overweight
Price Target: $74 → $83
Current: $72.51
Upside: +14.47%
Intra-Cellular Therapies
Nov 4, 2024
Maintains: Overweight
Price Target: $81 → $89
Current: $126.20
Upside: -29.48%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $61.53
Upside: +77.15%
Incyte
Oct 30, 2024
Maintains: Neutral
Price Target: $65 → $71
Current: $71.93
Upside: -1.29%
Alkermes
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $29.47
Upside: -11.77%
Ascendis Pharma
Oct 23, 2024
Maintains: Overweight
Price Target: $180 → $174
Current: $128.13
Upside: +35.80%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $9.89
Upside: +203.34%
Sep 19, 2024
Downgrades: Neutral
Price Target: $52 → $57
Current: $54.80
Upside: +4.01%
Aug 26, 2024
Maintains: Neutral
Price Target: $50 → $55
Current: $31.43
Upside: +74.99%
Aug 26, 2024
Maintains: Neutral
Price Target: $248 → $280
Current: $246.27
Upside: +13.70%
Aug 19, 2024
Maintains: Overweight
Price Target: $190 → $202
Current: $121.18
Upside: +66.69%
Jul 10, 2024
Maintains: Overweight
Price Target: $70 → $66
Current: $29.02
Upside: +127.43%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $37.35
Upside: +44.58%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $46.95
Upside: -16.93%
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $358.93
Upside: -16.42%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $9.36
Upside: +38.89%
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $26.17
Upside: -35.04%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.89
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $9.88
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.21
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.56
Upside: -
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $7.45
Upside: +34.23%
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $32.66
Upside: +132.70%
Mar 8, 2022
Upgrades: Overweight
Price Target: $204 → $240
Current: $4.65
Upside: +5,061.29%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.85
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $0.94
Upside: +2,240.43%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.69
Upside: +914.49%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $12.74
Upside: +111.93%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.62
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.40
Upside: -
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $3.55
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $5.25
Upside: -